Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company. The Companyâ€™s Trappsol Cyclo, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C1, a rare and fatal genetic disease, (NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is also engaged in conducting a Phase 2b clinical trial using Trappsol Cyclo intravenously in early Alzheimerâ€™s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimerâ€™s disease (NCT03624842).

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq 16:00:00 2025-03-25 EDT			5-day change	1st Jan Change
0.7206 ^USD	+1.39%		-.--%	-

04-22	Cyclo Therapeutics Enters into Exclusive Licensing Agreement with Massachusetts Institute of Technology	CI
25-08-27	Cyclo Therapeutics Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism	CI

Market Cap	16.97M 14.71M 13.78M 12.57M 23.63M 1.62B 23.99M 162M 63.35M 811M 63.73M 62.34M 2.7B	P/E 2022	-0.78x	P/E 2023	-1.29x
Enterprise Value	8.76M 7.59M 7.11M 6.49M 12.19M 835M 12.38M 83.63M 32.69M 418M 32.89M 32.17M 1.39B	EV / Sales 2022	7.63x	EV / Sales 2023	34.6x
Free-Float	51.95%	Yield 2022 *	-	Yield 2023	-

04-22	Cyclo Therapeutics Enters into Exclusive Licensing Agreement with Massachusetts Institute of Technology	CI
25-08-27	Cyclo Therapeutics Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism	CI
25-07-18	Cyclo Therapeutics, Inc. Announces Resignation of N. Scott Fine as Chief Executive Officer, Effective July 31, 2025	CI
25-06-18	Cyclo Therapeutics, Inc. Announces Continuation of Its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1	CI
25-03-27	Cyclo Therapeutics, Inc.(NasdaqCM:CYTH) dropped from S&P TMI Index	CI
25-03-26	Rafael Closes Merger With Cyclo Therapeutics	MT
25-03-26	Rafael Holdings Completes Merger With Cyclo Therapeutics Following Shareholder Approvals	RE
25-03-25	Cyclo Therapeutics, Inc.(NasdaqCM:CYTH) dropped from NASDAQ Composite Index	CI
25-03-24	Rafael Holdings, Inc. completed the acquisition of remaining 33.3% stake of Cyclo Therapeutics, Inc. from Armistice Capital Master Fund Ltd., fund managed by Armistice Capital LLC, Novit, L.P., Hercules Capital, Inc. (NYSE: HTGC) and others.	CI
25-03-06	Cyclo Therapeutics Inc Issues $2.5 Million Convertible Promissory Note To Rafael Holdings	RE
25-03-05	Cyclo Therapeutics, Inc. announced that it has received $2.5 million in funding from Rafael Holdings, Inc.	CI
25-02-07	Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC(TM) Open-Label Sub-Study in Patients (< 3 Years Old)	RE
25-02-07	Cyclo Therapeutics, Inc. Presents Positive Preliminary Data from Ongoing Phase 3 Transportnpc Open-Label Sub- Study in Patients	CI

24-08-27	Maxim Downgrades Cyclo Therapeutics to Hold From Buy	MT
24-08-23	HC Wainwright Downgrades Cyclo Therapeutics to Neutral From Buy	MT
24-05-01	HC Wainwright Starts Cyclo Therapeutics With Buy Rating, $3 Price Target	MT
23-09-27	Maxim Upgrades Cyclo Therapeutics to Buy From Hold With $4 Price Target	MT
23-03-20	Maxim Group Downgrades Cyclo Therapeutics to Hold From Buy	MT

Cyclo Therapeutics, Inc. Stock

Stocks

CYTH

US23254X2018

Pharmaceuticals

Valuation: Cyclo Therapeutics, Inc.

Latest news : Cyclo Therapeutics, Inc.

Analysts' recommendations: Cyclo Therapeutics, Inc.

Press Releases: Cyclo Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Cyclo Therapeutics, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Income Statement and Estimates

25-03-26	Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals	AQ
25-02-20	CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH	BU
25-02-10	Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing phase 3 TransportNPC Open-Label Sub-Study in Patients	AQ
25-02-07	Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)	BU
25-01-15	Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium 2025	AQ

Manager	Title	Age	Since
Charles Strattan CEO	Chief Executive Officer	80	2013-09-22
Jeffrey Tate CEO	Chief Executive Officer	68	2014-07-03

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/27/25	William Conkling	Free	Director	27,654	0.0966%
2/27/25	Vivien Wong	Free	Director	25,140	0.0879%
2/27/25	Randall Toig	Free	Director	33,311	0.1164%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CYCLO THERAPEUTICS, INC.	+1.39%	-.--%	-.--%	-52.59%	20.73M
ELI LILLY AND COMPANY	+0.43%	+4.31%	+90.84%	+130.99%	1,088B
JOHNSON & JOHNSON	+0.41%	+1.27%	+50.98%	+50.05%	629B
ABBVIE INC.	-0.53%	+1.04%	+25.23%	+63.46%	440B
ROCHE HOLDING AG	-0.31%	-0.14%	+45.86%	+37.51%	359B
NOVARTIS AG	-0.24%	-1.02%	+27.05%	+36.27%	291B
ASTRAZENECA PLC	-0.45%	-1.69%	+1.80%	+4.82%	245B
AMGEN INC.	+0.45%	+2.05%	+46.04%	+58.54%	225B
NOVO NORDISK A/S	-0.87%	+1.31%	-8.73%	-51.97%	204B
GILEAD SCIENCES, INC.	+0.07%	+3.12%	+13.21%	+69.84%	168B
Average	+0.04%	+1.14%	+29.23%	+34.69%	364.92B
Weighted average by Cap.	+0.04%	+1.93%	+48.65%	+66.14%

	2022	2023
Net sales	1.38M 1.19M 1.12M 1.02M 1.92M 131M 1.94M 13.14M 5.13M 65.7M 5.17M 5.05M 219M	1.08M 933K 874K 797K 1.5M 103M 1.52M 10.28M 4.02M 51.41M 4.04M 3.95M 171M
Net income	-15.45M -13.39M -12.54M -11.44M -21.51M -1.47B -21.84M -148M -57.66M -738M -58.01M -56.75M -2.46B	-20.06M -17.38M -16.28M -14.85M -27.92M -1.91B -28.35M -191M -74.86M -958M -75.31M -73.67M -3.19B
Net Debt	-1.54M -1.34M -1.25M -1.14M -2.15M -147M -2.18M -14.74M -5.76M -73.71M -5.79M -5.67M -246M	-8.21M -7.12M -6.67M -6.08M -11.43M -783M -11.61M -78.42M -30.65M -392M -30.84M -30.17M -1.31B

3 years	0.55	2.12
5 years	0.55	8.3
10 years	0.55	118